LIFECORE BIOMEDICAL, INC. DE

Lifecore Biomedical announced a new agreement with a global pharmaceutical company for technical transfer and commercial manufacturing of an injectable suspension product for neurological disorders. This significant win marks the seventh late-stage program agreement for Lifecore in the past seven months, demonstrating strong business development momentum. The agreement underscores confidence in Lifecore's technical expertise in producing higher-viscosity and complex pharmaceutical products, positioning them as a valuable partner for multinational pharmaceutical companies.

Lifecore Biomedical, Inc. stockholders approved the 2026 Stock Incentive Plan at the annual meeting on June 4, 2026. This plan authorizes the issuance of 2,500,000 shares of Common Stock and will become effective on October 16, 2026, replacing the 2019 Plan. Additionally, stockholders elected nine directors, ratified KPMG LLP as the independent auditor for 2026, and approved the non-binding advisory proposal on executive compensation.

Lifecore Biomedical, Inc. announced a new manufacturing services agreement with a leading provider of ophthalmic disease management solutions. The agreement entails process development and technical transfer services, preparing for potential commercial manufacturing of an injectable ophthalmic product following regulatory approval. This program, which involves reformulating a commercially approved product into pre-filled syringes, marks the sixth addition to Lifecore's late-stage pipeline in seven months, strengthening its growth strategy.

Lifecore Biomedical, Inc. announced its participation in the William Blair 46th Annual Growth Stock Conference, scheduled for June 2-4, 2026, in Chicago, IL. CEO Paul Josephs and CFO Ryan Lake will represent the company and engage in investor meetings. This event allows Lifecore to connect with the investment community.

Lifecore Biomedical reported a significant decrease in total revenues to $23.19 million for the three months ended March 31, 2026, down from $35.15 million in the comparable prior period. The company's net loss slightly increased to $(14.98) million, or $(0.43) per share. Despite the revenue decline, net cash provided by operating activities improved to $4.70 million, and the company saw positive developments in its legal matters, including the conclusion of an SEC investigation with no action and preliminary approval for a class action settlement.

Lifecore Biomedical reported first-quarter 2026 revenues of $23.2 million, a 34% decrease year-over-year, with a net loss of $15.0 million. Adjusted EBITDA also declined to $1.0 million from $5.7 million in the prior year. Despite the financial declines, the company reaffirmed its 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), citing successful execution of growth strategies, new program signings, and ongoing cost containment initiatives.

Lifecore Biomedical announced its first quarter 2026 results, reporting a significant 34% year-over-year decrease in revenues to $23.2 million and an increased net loss of $15.0 million. Despite the financial decline, the company reaffirmed its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing continued execution of its growth strategy and ongoing cost containment initiatives. Lifecore also highlighted the signing of three new commercial site transfer programs and the successful launch of a new ERP system.

Lifecore Biomedical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Stockholders will vote on the election of nine directors, the ratification of KPMG LLP as the independent auditor, an advisory proposal on executive compensation, and the approval of the 2026 Stock Incentive Plan. The record date for voting is April 6, 2026.

Lifecore Biomedical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, with a record date of April 6, 2026. Stockholders will vote on the election of nine directors, the ratification of KPMG LLP as the independent auditor, an advisory proposal on executive compensation, and the approval of the 2026 Stock Incentive Plan. The company also noted ongoing legal proceedings initiated by 22NW Fund, LP.

Lifecore Biomedical, Inc. announced the grant of a restricted stock unit (RSU) award for 5,000 shares of its common stock to a newly hired employee, effective April 20, 2026. This award, approved by the compensation committee, serves as a material inducement for the employee to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment.